EP4359439A1 — Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
Assigned to Yeda Research and Development Co Ltd · Expires 2024-05-01 · 2y expired
What this patent protects
A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epi…
USPTO Abstract
A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody..
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.